Pathogenesis of Myopathy in Models of Myotonic Dystrophy
Pathogenesis of Myopathy in Models of Myotonic Dystrophy
批准号:
7900632
负责人:
CHARLES A THORNTON
金额:
$7.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-18 至 2010-09-17
关键词:
3&apos Untranslated RegionsACTA1 geneAgeAllelesAlternative SplicingApoptosisBiogenesisBiological AssayBreedingBromodeoxyuridineCalciumCell DeathCell NucleusCharacteristicsChloride IonChloridesChromatinChronicComputer AnalysisDNADefectDevelopmentElectron MicroscopyElectroporationElementsEmbryoEmployee StrikesEventExonsFiberGenetic TranscriptionGrowth FactorHumanImageInjuryIntronsKineticsKnock-outLeadLengthMessenger RNAMetabolismModelingMorphologyMusMuscleMuscle FibersMyoblastsMyopathyMyotoniaMyotonic DisordersMyotonic DystrophyNatural regenerationNeonatalNuclearNuclear InclusionPathogenesisPathway interactionsPatientsPatternPhysical condensationPhysiologicalPoly(A) TailPositioning AttributePredispositionProtein IsoformsProteinsPumpRNARNA ProcessingRNA SplicingRegulationResearch PersonnelRibonucleasesRoleSarcoplasmic ReticulumSkeletal MuscleSymptomsTerminal Repeat SequencesTestingTimeToxic effectTranscriptTransgenesTransgenic MiceTransgenic ModelUnit of MeasureWild Type MouseWithdrawalWorkcDNA Expressioncomparativedesignexpression vectorfetalgain of functiongene inductionindexingmouse modelmutantmyogenesisoverexpressionpostnatalprogramsrepairedresearch studysatellite cellskeletal muscle wastinguptakewasting
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Myotonic dystrophy type 1 [DM1] leads to maldevelopment, myotonia, and wasting of skeletal muscle. DM1 is caused by an unstable CTG repeat expansion in the 3' untranslated region of DMPK. Our central hypothesis is that skeletal muscle findings in DM1 result from a toxic effect of repeat expansion transcripts. Support for this hypothesis comes from studies of HSALR transgenic mice that express CUG expansion RNA in muscle. (CUG)n transcripts accumulate in nuclear foci, leading to a myotonic myopathy that is similar to DM1. Our working model postulates the following sequence of events: expression of CUG expansion RNA -> accumulation of (CUG)n RNA in nuclear foci -> sequestration of muscleblind [Mbnl] proteins in nuclear foci -> abnormal regulation of alternative splicing -> expression of inappropriate splice isoforms -> symptoms of DM. We now have evidence that this model can explain certain aspects of DM1, such as, chloride channelopathy and myotonia. We plan to extend this model and define its limits. First, we will compare patterns of alternative splicing in HSALR, Mbnll knockout, and wild-type mice and test the hypothesis that CUG expansion RNA compromises a specific developmental program of alternative splicing that depends on Mbnl1, the predominant Mbnl protein expressed in muscle. A striking example of aberrant splicing involves Serca1, the calcium re-uptake pump in sarcoplasmic reticulum. The physiologic significance of mis-splicing Serca1 will be determined by calcium imaging. Second, there is little information about metabolism of (CUG)n transcripts. We have derived transgenic mice for inducible expression of CUG expansion transcripts. These mice will be used to compare the accumulation and degradation of transcripts with or without an expanded CUG repeat. We also will test the hypothesis that overexpression of nuclear mRNA-degradases can accelerate clearance of poly-CUG RNA. Third, we will assess myonuclear morphology and bromodeoxyuridine incorporation in HSA(LR) mice to test the hypothesis that accumulation of CUG expansion RNA leads to nuclear demise. In related experiments we will investigate the mechanism of cell death that occurs in HSA(LR) myoblasts when growth factors are withdrawn. Fourth, we have derived transgenic mice with cre-activation alleles to develop models for DM1-related maldevelopment and wasting and test the hypothesis that CUG expansion RNA interferes with muscle differentiation.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
Ribonuclear foci at the neuromuscular junction in myotonic dystrophy type 1.
强直性肌营养不良 1 型神经肌肉接头处的核糖核病灶。
DOI:
10.1016/j.nmd.2006.12.015
发表时间:
2007
期刊:
Neuromuscular disorders : NMD
影响因子:
--
作者:
[Wheeler,TM, Krym,MC, Thornton,CA]
通讯作者:
Thornton,CA
DOI:
10.1016/j.nbd.2010.02.004
发表时间:
2010-07
期刊:
Neurobiology of disease
影响因子:
6.1
作者:
[Nakamori M, Thornton C]
通讯作者:
Thornton C
DOI:
10.1021/ja9020149
发表时间:
2009-07-22
期刊:
Journal of the American Chemical Society
影响因子:
15
作者:
[Pushechnikov A, Lee MM, Childs-Disney JL, Sobczak K, French JM, Thornton CA, Disney MD]
通讯作者:
Disney MD
Therapeutic Modulation of Myotonic Muscular Dystrophy
-
批准号:10222788
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Therapeutic Modulation of Myotonic Muscular Dystrophy
-
批准号:9133482
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Biomarkers of therapeutic response in myotonic dystrophy
-
批准号:8952034
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Therapeutic Modulation of Myotonic Muscular Dystrophy
-
批准号:9005275
-
项目类别:
-
资助金额:$33.17万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Biomarkers of therapeutic response in myotonic dystrophy
-
批准号:9098817
-
项目类别:
-
资助金额:$19.19万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Therapeutic Modulation of Myotonic Muscular Dystrophy
-
批准号:9301054
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Therapeutic Modulation of Myotonic Muscular Dystrophy
-
批准号:9984584
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2015
-
负责人:CHARLES A THORNTON
-
依托单位:
Antisense oligonucleotide treatment for myotonic dystrophy
-
批准号:8467066
-
项目类别:
-
资助金额:$172.88万
-
财政年份:2011
-
负责人:CHARLES A THORNTON
-
依托单位:
Antisense oligonucleotide treatment for myotonic dystrophy
-
批准号:8658859
-
项目类别:
-
资助金额:$77.23万
-
财政年份:2011
-
负责人:CHARLES A THORNTON
-
依托单位:
Antisense oligonucleotide treatment for myotonic dystrophy
-
批准号:8241912
-
项目类别:
-
资助金额:$92.1万
-
财政年份:2011
-
负责人:CHARLES A THORNTON
-
依托单位:
Antisense oligonucleotide treatment for myotonic dystrophy
-
批准号:8033858
-
项目类别:
-
资助金额:$55.45万
-
财政年份:2011
-
负责人:CHARLES A THORNTON
-
依托单位:
Inhibitors of MBNL1 - poly(CUG)binding
-
批准号:7760269
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2009
-
负责人:CHARLES A THORNTON
-
依托单位:
Experimental Therapy of Myotonic Dystrophy
-
批准号:7535923
-
项目类别:
-
资助金额:$65.6万
-
财政年份:2008
-
负责人:CHARLES A THORNTON
-
依托单位:
Therapeutic approach targeting RNA disease in myotonic dystrophy
-
批准号:7239389
-
项目类别:
-
资助金额:$16.5万
-
财政年份:2007
-
负责人:CHARLES A THORNTON
-
依托单位:
Model of OPMD with constitutive PABPN1 expression
-
批准号:7289126
-
项目类别:
-
资助金额:$13.48万
-
财政年份:2007
-
负责人:CHARLES A THORNTON
-
依托单位:
Therapeutic approach targeting RNA disease in myotonic dystrophy
-
批准号:7437250
-
项目类别:
-
资助金额:$19.94万
-
财政年份:2007
-
负责人:CHARLES A THORNTON
-
依托单位:
Model of OPMD with constitutive PABPN1 expression
-
批准号:7494551
-
项目类别:
-
资助金额:$16.84万
-
财政年份:2007
-
负责人:CHARLES A THORNTON
-
依托单位:
FUNCTIONAL GENOMICS IN MUSCULAR DYSTROPHY
-
批准号:7200088
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2005
-
负责人:CHARLES A THORNTON
-
依托单位:
CLINICAL TRIAL OF INSULIN-LIKE GROWTH FACTOR-1 IN AMYOTROPHIC LATERAL SCLEROSIS
-
批准号:7200103
-
项目类别:
-
资助金额:$0.77万
-
财政年份:2005
-
负责人:CHARLES A THORNTON
-
依托单位:
Clinical Trial of Insulin-Like Growth Factor-1 in ALS
-
批准号:7040056
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2004
-
负责人:CHARLES A THORNTON
-
依托单位:
海外基金